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Abstract
Current guidelines for the diagnosis and treat-
ment of osteoporosis do not address the risks to
bone density and the likelihood of fracture that may
be associated with inhaled corticosteroid treat-
ment for asthma. This review outlines an approach
to the use of bone densitometry in clinical prac-
tice for the diagnosis, prevention, and treatment
of osteoporosis in asthmatic patients receiving
inhaled corticosteroid therapy.
Diagnosis of Osteoporosis
Bone densitometry by dual-energy x-ray absorp-
tiometry (DXA) allows osteoporosis to be diag-
nosed and corrective treatment initiated before
clinical fractures occur.1The hip and lumbosacral
spine are the best validated sites for an objective
measurement of bone mineral density (BMD)
from which to estimate fracture risk. The degree
of risk is estimated to increase 1.5- to 3-fold for
every standard deviation decrease in BMD.
To facilitate clinical interpretation of the test
result, BMD measured in absolute terms is con-
verted to a T-score and/or Z-score. The T-score
compares the patient’s measured BMD with the
average value for healthy young adults when
their peak bone mass is normally attained (about
30 years of age). T-score values at or below 2.5
indicate osteoporosis and a clinically important
increase in fracture risk.2 The Z-score compares
the patient’s measured BMD with that of a pop-
ulation of healthy persons of the same age and sex
as the patient, that is, it “controls” for the poten-
tially confounding effects of concurrent reductions
in BMD that relate to advancing age.
Decisions about the need for preventive or cor-
rective antiosteoporosis treatment in a particular
patient or patient group require that the presence
or absence of clinical risk factors for fracture be
taken into consideration, as well as the BMD mea-
surement score.3Relevant risk factors include the
patient’s age (> or < 65 years) and current and past
exposure to corticosteroid (glucocorticoid) ther-
apy (Table 1).
DXA is recommended for patients who have
been exposed to systemic corticosteroid therapy for
3 months or longer.3The current Canadian guide-
lines for the management of osteoporosis do not
cite inhaled corticosteroid (ICS) therapy as a risk
factor that merits densitometry (see Table 1).
Contrary Effects of ICS Therapy on 
Bone Density and the Risk of Fracture
Low daily doses of ICS administered to adults for
10 ± 5.5 years (Figure 1)4 or to children for 4 to
6 years5 did not significantly reduce BMD. How-
ever, high-dose ICS therapy has been shown to
reduce BMD in adults with asthma4 or chronic
obstructive pulmonary disease6 and in pre-
menopausal asthmatic women.7
As much as 45% of the variability in BMD that
may be demonstrable among elderly asthmatic
patients cannot be explained on the basis of their
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past or current exposures to corticosteroid therapy
or other clinically identifiable risk factors for osteo-
porosis.4,8 Genetic determinants, as yet not
identified, are thought to account for much of this
variability. Some identifiable factors that may act
to conserve or restore BMD in asthmatic adults
receiving long-term ICS therapy, and thereby
reduce their risk of fracture, are shown in Table 2.
A cross-sectional survey by DXA in asth-
matic adults previously treated with prednisone
found that higher current daily doses of ICS were
associated with reduced Z-score values for BMD
(see Figure 1), whereas in the same patient group,
larger cumulative lifetime exposures to ICS cor-
related paradoxically with higher BMD values (see
Table 2) and a corollary, clinically important,
dose-related reduction in the numbers of patients
at risk of fracture (Table 3).4 This illustrates the
fact that despite prolonged and continuing expo-
sure to prednisone, osteoporosis remains a poten-
tially reversible process, and substituting ICS for
current prednisone use may, in many patients,
conserve or improve BMD sufficiently to reduce
the risk of fracture to a level approximating that
of healthy persons of the same age and sex who
have never been exposed to inhaled or oral cor-
ticosteroid therapy (see Table 3). Prednisone with-
drawal and increased physical activity conse-
quent to improved asthma control may be
proximate causes of this favourable outcome of
ICS treatment (see Table 2).
Prevention and Treatment of 
Glucocorticoid-Induced Osteoporosis
It is recommended that the presence or absence of
clinical risk factors for osteoporosis and fracture
Table 1  Factors That Identify People Who Should Be Assessed for Osteoporosis
Major Risk Factors Minor Risk Factors
Age > 65 yr Rheumatoid arthritis
Vertebral compression fracture Past history of clinical hyperthyroidism
Fragility fracture after age 40 yr Chronic anticonvulsant therapy
Family history of osteoporotic fracture Low dietary calcium intake
(especially maternal hip fracture) Smoker
Systemic glucocorticoid therapy Excessive alcohol intake
of > 3 mo duration Excessive caffeine intake
Malabsorption syndrome Weight < 57 kg
Primary hyperparathyroidism Weight loss > 10% of weight at age 25 yr
Propensity to fall Chronic heparin therapy
Osteopenia apparent on radiograph
Hypogonadism
Early menopause (before age 45 yr)
Adapted from Brown JP et al.3
Figure 1  Regression of lumbosacral bone mineral den-
sity on the daily dose of inhaled corticosteroid in a cross-
sectional analysis of bone density in 69 corticosteroid-
dependent adults with moderate to severe chronic
asthma.4 The calculated mean regression (± 95% con-
fidence limits) is adjusted to control for the effects of
age, sex, years of estrogen use, physical activity, the cur-
rent daily dose of prednisone, years of prednisone use,
and the cumulative lifetime dose of inhaled corticos-
teroid. Bone density declined significantly on the cur-
rent daily dose of inhaled corticosteroid (p = .013
analysis of covariance). At doses ≤ 1.0 mg/d, bone
density did not differ significantly from normal. SEM
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be documented and a baseline DXAmeasurement
secured in patients who are commencing ICS ther-
apy and appear likely to need a maintenance dose
> 1.0 mg beclomethasone dipropionate (BDP) per
day or a systemically equivalent dose of an alter-
native ICS.9Depending on the DXAresult and clin-
ical considerations, appropriate antiosteoporosis
therapy may be indicated.
Current guidelines recommend that all patients
receiving glucocorticoid therapy take an oral cal-
cium supplement daily (at least 1,000 mg of Ca++)
plus activated vitamin D2.3 For patients who use
medium to high doses of glucocorticoid, activated
vitamin D3(cholecalciferol) is preferred over vit-
amin D2 because the latter is less potent.
In asthma patients deemed to be potentially
at risk despite normal BMD, an orally adminis-
tered bisphosphonate antiresorptive agent
(etidronate, alendronate, risedronate) may be
indicated to prevent bone loss.2,3,10,11 In patients
who are already at risk because of established
glucocorticoid-induced osteoporosis, bisphos-
phonates have the capacity to restore bone mass
and thus reduce the risk of vertebral fracture.3
They are currently recommended as first-line
therapy for the prevention or treatment of osteo-
porosis in men or postmenopausal women who
use prednisone at doses ≥ 5 mg/d.3 However, bis-
phosphonates are generally not appropriate for
young women or children.12 Bisphosphonates
and calcium should not be taken at the same
time of day because the calcium impairs absorp-
tion of the bisphosphonate.
Therapeutic Tactics
It is important that the daily dose of ICS be
adjusted individually for each patient to ensure that
it is adequate to fully control day-to-day asthma
symptoms, to eliminate the need for long-term
prednisone, and to prevent exacerbations of
asthma that trigger periodic intervention with
high and potentially bone-depleting doses of pred-
nisone. The bone-depleting effect of episodic
high-dose prednisone use has been shown to per-
sist long after the transient high-dose regimen
has been terminated.13
The daily dose of ICS should be sufficient to
facilitate daily weight-bearing (impact type) phys-
ical activity.14 A regular exercise regimen suited
to the particular needs and capacity of each patient
should be encouraged.3
With a high-potency antiasthmatic ICS such
as fluticasone, most patients achieve an optimal
therapeutic response with a dose ≤ 0.5 mg/d.15,16
Higher doses increase the risk of adverse sys-
temic effects disproportionately.15
For patients who need a high daily dose of ICS
to ensure optimum control of unstable asthma,
the current treatment of choice is a combination
formulation such as fluticasone plus salmeterol17
or budesonide plus formoterol.18 Administered
twice daily, these products offer the advantage
that equivalent asthma control may be achieved
with a lower and safer daily dose of ICS.17,18
Alternatively, in patients with unstable mod-
erate to severe chronic asthma, administering
Table 2 Correlates of Higher Lumbosacral Bone Density Z-Score Values 
in ICS-Treated Asthmatic Adults*
Correlates of Higher Bone Density p Value (ANCOVA)
Larger cumulative lifetime dose of ICS .002
Lower current daily dose of ICS .013
Fewer years of prednisone exposure .032
Greater physical activity .042
More years of supplemental estrogen use .058
Adapted from Toogood JH et al.4
ANCOVA= analysis of covariance; ICS = inhaled corticosteroid.
*N = 69. Age: 59.9 ± 13.3 yr (SD).
Years of steroid exposure (mean ± SD): prednisone = 10.7 ± 9.7 yr, ICS = 10.1 ± 5.5 yr.approved doses of a standard formulation of
budesonide (without the adrenergic component)
in four rather than two divided treatments each day
can increase the antiasthmatic potency of the ICS
as much as six to sevenfold (Figure 2)19 and mate-
rially improve clinical outcomes20 without an
accompanying increase in systemic risks or
cost.19,20 For many patients, cost is likely to be a
major determinant of whether ICS is prescribed
or dispensed.21
For patients with mild persistent asthma, the
combination of salmeterol plus fluticasone is more
effective than the antileukotriene montelukast.17 On
the other hand, in patients with more severe asthma
suboptimally controlled on low or moderate doses
of ICS, high-dose zafirlukast may provide an
effective nonsteroidal alternative to increasing
the corticosteroid dose.22
For postmenopausal asthmatic women, an
estrogen and progesterone supplement is recom-
mended to reduce the risk of fracture.3 To maxi-
mize its bone-conserving effect, the estrogen
replacement should commence soon after the
advent of menopause. 
Bisphosphonate therapy currently constitutes
a first-line choice for the treatment or prevention
of glucocorticoid-induced osteoporosis.3 Caution
is advised with respect to its use in premenopausal
women.23
Applications of DXAin Clinical Practice
Bone densitometry is deemed appropriate where
the results of the test may reasonably be expected
to directly influence patient management.1
Patients with at least one major or two minor
risk factors for fracture are candidates for DXA(see
Table 1). Systemic glucocorticoid therapy for more
than 3 months is identified as a major risk factor.1,3
DXAis also recommended for asthmatic adults who
require an ICS dose with a systemic potency equal
to or exceeding that of 1.0 mg BDP per day.9
However, regardless of the daily dose, DXA
should be sought routinely in elderly asthmatic
patients receiving ICS or prednisone treatment
because a majority may exhibit a clinically impor-
tant (and potentially treatable) increase in fracture
risk. Furthermore, the degree of risk or nonrisk
in a particular patient cannot be accurately esti-
mated from any combination of the identifiable
risk factors for osteoporosis and/or common clin-
ical features of hypercortisonism and/or records
of their current or past inhaled and/or oral corti-
costeroid exposure, with or without accompany-
ing measurement of laboratory indices of bone
metabolism.8
Contradictory findings have been reported
as to the accumulative effects of prolonged ICS
treatment on BMD.4–7,24,25 It has been suggested
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Table 3 Cumulative Dose-Related Reduction in Fracture Risk Achieved by Steroid-Dependent 
Asthmatic Adults after Substituting ICS for Past Prednisone Therapy
Percent of Group with Normal Bone Density*
Cumulative Lifetime ICS Exposure Men (n = 26) Women (n = 43)†
(10.1 ± 5.5 yr) Age 58.5 ± 17.6 (SD) yr Age 60.8 ± 9.6 (SD) yr
≤3  g ‡ 20 50
> 3 g‡ 40§ 65§
Adapted from Toogood JH et al.4
ICS = inhaled corticosteroid.
*Lumbosacral bone mineral density Z-score (LBMD-Z): +4 to 1.
†All postmenopausal women received supplemental estrogen. 
‡Median lifetime cumulative ICS exposure = 3 g. Lifetime prednisone exposures were balanced equally between the higher
and lower lifetime ICS exposure subgroups (p = .87).4
§Larger lifetime exposures to ICS were associated with more normal LBMD-Z scores (p = .002 analysis of covariance) and a
substantially larger number of patients with Z-scores indicating no increase in fracture risk.432 Allergy, Asthma, and Clinical Immunology / Volume 1, Number 1, October 2004
that patients with a cumulative lifetime exposure
to ICS that exceeds 5.0 g should be candidates for
DXAand, depending on the result, considered for
preventive intervention to reduce their risk of
fracture in later life.25 The preliminary measure-
ment by DXAis important because some patients
retain normal BMD values despite prolonged
exposure to ICS therapy (see Figure 1 and Table
3). Therefore, they have no appreciable clinical
need for active intervention with antiresorptive
therapy.
A T-score value at or below 2.5 as deter-
mined by DXA indicates established osteoporo-
sis and an important increase in fracture risk.2 T-
scores in the osteopenic range between 1 and
2.5 indicate a need for antiresorptive treatment
to prevent further bone depletion.2
Where the diagnosis of osteopenia or osteo-
porosis has been confirmed by DXA and
corrective bisphosphonate therapy initiated, the
response to the bisphosphonate should be moni-
tored by serial DXAexaminations at intervals of
about 1 to 3 years.3
It is not yet known whether the early intro-
duction of long-term low-dose ICS therapy in
young children with mild asthma may ultimately
reduce the peak bone mass that they attain at
maturity. A baseline DXA measurement may be
appropriate in such patients when they attain 30
years of age—with appropriate follow-up depend-
ing on the result.
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